Shares of Kadmon Co. (NYSE:KDMN) have earned an average recommendation of “Hold” from the six brokerages that are covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $13.25.
A number of equities analysts have recently issued reports on the company. Zacks Investment Research raised Kadmon from a “hold” rating to a “buy” rating and set a $4.25 target price for the company in a report on Friday, January 12th. Jefferies Group increased their target price on Kadmon to $16.00 and gave the stock a “buy” rating in a report on Tuesday, February 13th. HC Wainwright reissued a “buy” rating and issued a $25.00 target price on shares of Kadmon in a report on Friday, March 9th. Finally, Piper Jaffray reissued a “positive” rating and issued a $9.00 target price (up from $7.00) on shares of Kadmon in a report on Tuesday, February 13th.
A number of hedge funds have recently added to or reduced their stakes in the stock. Sawtooth Solutions LLC acquired a new stake in Kadmon during the 4th quarter valued at $799,000. Goldentree Asset Management LP increased its holdings in Kadmon by 673.6% during the 4th quarter. Goldentree Asset Management LP now owns 1,611,730 shares of the company’s stock valued at $5,834,000 after purchasing an additional 1,403,397 shares in the last quarter. BlueCrest Capital Management Ltd acquired a new stake in Kadmon during the 4th quarter valued at $241,000. Geode Capital Management LLC increased its holdings in Kadmon by 172.4% during the 4th quarter. Geode Capital Management LLC now owns 463,844 shares of the company’s stock valued at $1,679,000 after purchasing an additional 293,569 shares in the last quarter. Finally, Spark Investment Management LLC acquired a new stake in Kadmon during the 4th quarter valued at $868,000. 61.73% of the stock is owned by hedge funds and other institutional investors.
Shares of KDMN stock traded down $0.05 during mid-day trading on Wednesday, reaching $4.14. The stock had a trading volume of 29,523 shares, compared to its average volume of 862,996. Kadmon has a one year low of $2.05 and a one year high of $5.86. The company has a market capitalization of $329.52, a P/E ratio of -2.95 and a beta of 3.90.
Kadmon (NYSE:KDMN) last announced its quarterly earnings data on Tuesday, March 6th. The company reported ($0.24) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.36) by $0.12. The firm had revenue of $1.50 million during the quarter, compared to the consensus estimate of $3.07 million. During the same quarter in the prior year, the business posted ($0.50) EPS. Kadmon’s revenue was down 65.1% compared to the same quarter last year. equities analysts expect that Kadmon will post -1.11 EPS for the current year.
TRADEMARK VIOLATION NOTICE: “Kadmon Co. (KDMN) Receives $13.25 Average Target Price from Analysts” was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece on another site, it was stolen and republished in violation of U.S. & international trademark and copyright law. The legal version of this piece can be viewed at https://www.dispatchtribunal.com/2018/04/23/kadmon-co-kdmn-receives-13-25-average-target-price-from-analysts.html.
Kadmon Company Profile
Kadmon Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics within autoimmune and fibrotic, oncology, and genetic diseases. The company markets and distributes a portfolio of branded generic ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including those indicated for the management of rare diseases.
Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.